Janssen China Announces Inclusion of Innovative Drug Tremfya® in National Reimbursement Drug List

Renewal of 2 products,Two Products Adjust Payment Scope

BeijingJanuary 18, 2023PR Newswire -- Today, the National Healthcare Security Administration announced the "National Basic Medical Insurance, Work-related Injury Insurance, and Maternity Insurance Drug Catalog (2022 Edition)" (hereinafter referred to as the National Medical Insurance Catalog), whichJanssen China5An Innovative Drug Receives Good News, including innovative drugs for the treatment of moderate to severe plaque psoriasis in adultsTremfya^®(Guselkumab Injection)Successfully Included in the National Medical Insurance Catalog；Xian Janssen^®(Paliperidone Palmitate Injection - 3M) andImbruvica^®（Ibrutinib CapsulesSuccessful Renewal. In addition, there are two products in the catalog.Adjusted the scope of medical insurance payments, respectively, are innovative drugs for the treatment of attention deficit hyperactivity disorderFocalin^®(Methylphenidate Hydrochloride Sustained-Release Tablets) and innovative drugs for the treatment of schizophreniaSaphris^®(Paliperidone Palmitate Injection) covers immunology, oncology, neurology and psychiatry, further enhancing the accessibility and affordability of innovative drugs for patients.

Alisa Zheng, President of Janssen China, said:"Thanks to the various positive policies of the National Healthcare Security Administration, Xian Janssen's innovative products have been included in the medical insurance catalog."Has brought health benefits to more patients and families. Newly included in medical insurance this yearTremfya^®YesThe world's first approvedIL-23 Inhibitor, which can help a large number of psoriasis patients face each day with greater ease and convenience. As aDeeply Rooted in China for Nearly Four DecadesAs a pharmaceutical innovation enterprise, Xian Janssen has always closely cooperated with the Chinese government.Implement relevant medical insurance policies, actively responding to the nationalDeepen the Reform of the Medical Security System, helping to buildMulti-level Medical Security System. In the future, we will continue to focus on innovationFulfilling the Commitment to Chinese Society`, contributing to the realization of`The Vision of the Chinese People's Aspiration for a Better Life, helping the Chinese governmentAdvance the Construction of Healthy China in an All-round Way。"

As of now,At Janssen China31Among the products that have already entered the Chinese market, there are30 drugs enter the National Medical Insurance Catalogue,Covering the most urgently needed therapeutic areas in China, such as oncology, immunology, neurology, pulmonary arterial hypertension, and infectious diseases. While supporting the Chinese government's efforts to promote the accessibility of innovative drugs, Janssen China is also committed to buildingNew Strategic Partnership, in collaboration with industry partnersJoin hands to promote the development of China's healthcare industry and contribute to the health and well-being of the Chinese people.

Appendix:

Innovative drugs included and renewed in the National Medical Insurance Catalog and their indications are as follows:

Tremfya^®(Guselkumab Injection) Successfully Included in the National Medical Insurance Catalog, Applicable to Adult Patients with Moderate to Severe Plaque Psoriasis Suitable for Systemic Treatment.

Xian Janssen^®(Paliperidone Palmitate Injection - 3M) Successfully Renewed, Applicable to Those Who Have Received Xeplion^®(Paliperidone Palmitate Injection (1-month formulation)) for schizophrenia patients who have received at least 4 months of adequate treatment.

Imbruvica^®(Ibrutinib Capsules) successfully renewed, with indications including: monotherapy for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy; monotherapy for the treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma; monotherapy for the treatment of patients with Waldenström's macroglobulinemia who have received at least one prior therapy, or as first-line treatment for Waldenström's macroglobulinemia patients unsuitable for chemoimmunotherapy; in combination with rituximab, for the treatment of patients with Waldenström's macroglobulinemia.

Innovative drugs with new indications included in the National Medical Insurance Catalog and their new indications are as follows:

Focalin^®(Methylphenidate Hydrochloride Sustained-Release Tablets) are suitable for the treatment of children and adolescents aged 6-17 years and adults aged 18-65 years with Attention Deficit Hyperactivity Disorder (ADHD) who meet the DSM-IV diagnostic criteria. The indications for adolescents and adults approved in 2021 have been included in the medical insurance reimbursement scope.

Innovative drugs and their indications for which medical insurance payment restrictions have been lifted are as follows:

Simplicta^®(Paliperidone Palmitate Injection), applicable for the treatment of acute and maintenance phases of schizophrenia.